Tracers′  clinical application status in the sentinel lymph node biopsy of breast cancer

doi:10.3760/cma.j.issn.1673-422X.2018.04.014

Abstract

Abstract: The treatment of breast cancer is becoming more individualized and minimally invasive, which makes sentinel lymph node biopsy becoming the standard treatment for axillary in patients with early-stage breast cancer who are negative in clinical axillary lymph nodes. Tracers image sentinel lymph nodes or lymphatic vessels for the successful detection of sentinel lymph node biopsy. Tracers selection is also more diverse, such as nano carbon mixed suspension, methylene blue, radioisotope, indocyanine green, etc. Different tracers and combined applications have their advantages and limitations. As for the selection of tracing methods, many factors need to be weighed.

Key words: Breast neoplasms, Sentinel lymph node biopsy, Tracer

Shi Manman, Chen Chuang, Li Zhiyu, Sun Shengrong. Tracers′ clinical application status in the sentinel lymph node biopsy of breast cancer[J]. Journal of International Oncology, 2018, 45(4): 245-249.

References

［1］ Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012［J］. CA Cancer J Clin, 2015, 65(2): 87-108. DOI: 10.3322/caac.21262. ［2］ Krag DN, Anderson SJ, Julian TB, et al. Sentinel-lymph-node resection compared with conventional axillarylymphnode dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B32 randomised phase 3 trial［J］. Lancet Oncol, 2010, 11(10): 927-933. DOI: 10.1016/S1470-2045(10)702072. ［3］ Tvedskov TF. Staging of women with breast cancer after introduction of sentinel node guided axillary dissection［J］. Dan Med J, 2012, 59(7): B4475. ［4］赵丽娟, 张晓红, 张珍, 等. 乳癌改良根治术前纳米炭注射时机的对比研究［J］. 四川医学, 2016, 37(6): 609-612. DOI: 10.16252/j.cnki.issn1004-0501-2016.06.009. ［5］张永松, 梁全琨, 钟玲, 等. 纳米炭和亚甲蓝联合核素示踪法在腔镜乳腺癌前哨淋巴结活组织检查中的对照研究［J］. 中华乳腺病杂志(电子版), 2015, 9(4): 231-235. DOI: 10.3877/cma.j.issn.1674-0807.2015.04.002. ［6］陈智, 覃庆洪, 练斌, 等. 纳米炭混悬液与美蓝在乳腺癌前哨淋巴结活检中的应用研究［J］. 实用癌症杂志, 2015, 30(9): 1320-1323. DOI: 10.3969/j.issn.1001-5930.2015.09.017. ［7］林启谋, 周毅, 李勇, 等. 纳米碳乳腺癌前哨淋巴结活检中的应用研究［J］. 吉林医学, 2012, 33(26): 5616-5617. ［8］范林军, 钟玲, 郭德玉, 等. 纳米炭对乳腺癌腋窝淋巴结示踪效果及其安全性的初步研究［J］. 中华乳腺病杂志(电子版), 2010, 4(3): 47-50. DOI: 10.3969/j.issn.1674-0807.2010.03.012. ［9］ Peek MC, Charalampoudis P, Anninga BA, et al. Blue dye for identification of sentinel nodes in breast cancer and malignant melanoma: a systematic review and metaanalysis［J］. Future Oncol, 2017, 13(5): 455-467. DOI: 10.2217/fon-2016-0255. ［10］ Giuliano AE, Kirgan DM, Guenther JM, et al. Lymphatic mapping and sentinel lymphadenectomy for breast cancer［J］. Ann Surg, 1994, 220(3): 391-401. ［11］ Varghese P, AbdelRahman AT, Akberali S, et al. Methylene blue dye—a safe and effective alternative for sentinel lymph node localization［J］. Breast J, 2008, 14(1): 61-67. DOI: 10.1111/j.15244741.2007.00519.x. ［12］ Bakhtiar N, Jaleel F, Moosa FA, et al. Sentinel lymph node identification by blue dye in patients with breast carcinoma［J］. Pak J Med Sci, 2016, 32(2): 448-451. DOI: 10.12669/pjms.322.9563. ［13］ Ang CH, Tan MY, Teo C, et al. Blue dye is sufficient for sentinel lymph node biopsy in breast cancer［J］. Br J Surg, 2014, 101(4): 383-389. DOI: 10.1002/bjs.9390. ［14］ Fattahi AS, Tavassoli A, Rohbakhshfar O, et al. Can methylene blue dye be used as an alternative to patent blue dye to find the sentinel lymph node in breast cancer surgery?［J］. J Res Med Sci, 2014, 19(10): 918-922. ［15］ He PS, Li F, Li GH, et al. The combination of blue dye and radioisotope versus radioisotope alone during sentinel lymph node biopsy for breast cancer: a systematic review［J］. BMC Cancer, 2016, 16(1): 107-119. DOI: 10.1186/s12885-016-2137-0. ［16］ Guo W, Zhang L, Ji J, et al. Evaluation of the benefit of using blue dye in addition to indocyanine green fluorescence for sentinel lymph node biopsy in patients with breast cancer［J］. World J Surg Oncol, 2014, 12: 290. DOI: 10.1186/1477-7819-12-290. ［17］王新华, 古力努尔·哈布力哈吉, 董占飞, 等. 99mTc硫胶体术前淋巴显像在乳腺癌前哨淋巴结活检中的应用［J］. 中国肿瘤临床, 2010, 37(21): 1227-1231. DOI: 10.3969/j.issn.1000-8179.2010.21.007. ［18］刘娟娟，孙晓，王春英，等. 乳腺癌前哨淋巴结活检术前淋巴显像的临床意义［J］. 山东医药, 2012, 52(5): 78-79. DOI: 10.3969/j.issn.1002-266X.2012.05.035. ［19］乔江华, 焦得闯, 卢振铎, 等. 术前淋巴结显像在乳腺癌前哨淋巴结活检中的应用价值［J］. 中国肿瘤, 2014, 23(4): 346-348. DOI: 10.11735/j.issn.1004-0242.2014.04.A016. ［20］ Serrano-Vicente J, Rayo-Madrid JI, Dominguez-Grande ML, et al. Role of SPECT-CT in breast cancer sentinel node biopsy when internal mammary chain drainage is observed［J］. Clin Transl Oncol, 2016, 18(4): 418-425. DOI: 10.1007/s12094-015-1384-x. ［21］ Niebling MG, Pleijhuis RG, Bastiaannet E, et al. A systematic review and meta-analyses of sentinel lymph node identification in breast cancer and melanoma, a plea for tracer mapping［J］. Eur J Surg Oncol, 2016, 42(4): 466-473. DOI: 10.1016/j.ejso.2015.12.007. ［22］刘琳, 张保宁, 杨红鹰, 等. 核素淋巴显像识别前哨淋巴结在乳腺癌治疗中的应用［J］. 中华乳腺病杂志(电子版), 2010, 4(3): 14-18. DOI: 10.3969/j.issn.1674-0807.2010.03.005. ［23］中国抗癌协会乳腺癌专业委员会. 中国抗癌协会乳腺癌诊治指南与规范(2015版)［J］. 中国癌症杂志, 2015, 25(09): 692-754. DOI: 10.3969/j.issn.1007-3696.2015.09.010. ［24］ Kitai T, Inomoto T, Miwa M, et al. Fluorescence navigation with indocyanine green for detecting sentinel lymph nodes in breast cancer［J］. Breast Cancer, 2005, 12(3): 211-215. ［25］ Inoue T, Nishi T, Nakano Y, et al. Axillary lymph node recurrence after sentinel lymph node biopsy performed using a combination of indocyanine green fluorescence and the blue dye method in early breast cancer［J］. Breast Cancer, 2016, 23(2): 295-300. DOI: 10.1007/s12282-014-0573-8. ［26］杨金梅, 崔莉青, 李雪. 吲哚菁绿脉管成像仪系统在乳腺癌术中前哨淋巴结活检中的应用［J］. 护理研究, 2016, 30(10): 1267-1268. DOI: 10.3969/j.issn.1009-6493.2016.10.037. ［27］ Sugie T, Kassim KA, Takeuchi M, et al. A novel method for sentinel lymph node biopsy by indocyanine green fluorescence technique in breast cancer［J］. Cancers (Basel), 2010, 2(2): 713-720. DOI: 10.3390/cancers2020713. ［28］ Sugie T, Sawada T, Tagaya N, et al. Comparison of the indocyanine green fluorescence and blue dye methods in detection of sentinel lymph nodes in earlystage breast cancer［J］. Ann Surg Oncol, 2013, 20(7): 2213-2218. DOI: 10.1245/s10434-013-2890-0. ［29］ Hirche C, Murawa D, Mohr Z, et al. ICG fluorescence-guided sentinel node biopsy for axillary nodal staging in breast cancer［J］. Breast Cancer Res Treat, 2010, 121(2): 373-378. DOI: 10.1007/s10549-010-0760-z. ［30］邹伟伟, 白玉, 王希龙, 等. 吲哚菁绿与纳米碳在乳腺癌前哨淋巴结活检中的对比研究［J］. 中国普通外科杂志, 2016, 25(11): 1627-1632. DOI: 10.3978/j.issn.1005-6947.2016.11.018. ［31］ Hunt KK, Ballman KV, Mccall LM, et al. Factors associated with local-regional recurrence after a negative sentinel node dissection results of the ACOSOG Z0010 trial［J］. Ann Surg, 2012, 256(3): 428-436. DOI: 10.1097/SLA.0b013e3182654494. ［32］ Hirano A, Kamimura M, Ogura K, et al. A comparison of indocyanine green fluorescence imaging plus blue dye and blue dye alone for sentinel node navigation surgery in breast cancer patients［J］. Ann Surg Oncol, 2012, 19(13): 4112-4116. DOI: 10.1245/s10434-012-2478-0. ［33］ Cong BB, Sun X, Song XR, et al. Preparation study of indocyanine greenrituximab: a new receptortargeted tracer for sentinel lymph node in breast cancer［J］. Oncotarget, 2016, 7(30): 47526-47535. DOI: 10.18632/oncotarget.10204. ［34］田崇麟, 孙晓, 刘雁冰, 等. 乳腺癌前哨淋巴结活检术新型示踪剂的动物模型研究［J］. 中国癌症杂志, 2016, 26(7): 569-573. DOI: 10.19401/j.cnki.1007-3639.2016.07.002. ［35］孔之华, 黄义方, 李娟娟, 等. 纳米炭与亚甲蓝示踪剂在乳腺癌腋窝前哨淋巴结活检中应用效果比较［J］. 广西医学, 2016, 38(6): 852-853, 858. DOI: 10.11675/j.issn.0253-4304.2016.06.28. ［36］邵志敏, 李俊杰. 2015版《中国抗癌协会乳腺癌诊治指南与规范》:外科部分解读［J］. 中华乳腺病杂志(电子版), 2016, 10(1): 1-5. DOI: 10.3877/cma.j.issn.1674-0807.2016.01.001. ［37］李艺, 王燕, 常婷, 等. 经皮超声造影提示前哨淋巴结性质对腋窝淋巴结良恶性评估的价值［J］. 上海交通大学学报(医学版), 2015, 35(9): 1320-1324. DOI: 10.3969/j.issn.1674-8115.2015.09.015. ［38］应海岳, 吴海涛. CT间接淋巴造影诊断舌癌颈淋巴结早期转移［J］. 温州医科大学学报, 2016, 46(9): 660-665. DOI: 10.3969/j.issn.2095-9400.2016.09.009. ［39］ Boughey JC, Ballman KV, Le-Petross HT, et al. Identification and resection of clipped node decreases the falsenegative rate of sentinel lymph node surgery in patients presenting with node-positive breast cancer (T0-T4, N1N2) who receive neoadjuvant chemotherapy: results from ACOSOG Z1071 (alliance)［J］. Ann Surg, 2016, 263(4): 802-807. DOI: 10.1097/SLA.0000000000001375. ［40］ Choy N, Lipson J, Porter C, et al. Initial results with preoperative tattooing of biopsied axillary lymph nodes and correlation to sentinel lymph nodes in breast cancer patients［J］. Ann Surg Oncol, 2015, 22(2): 377-382. DOI: 10.1245/s10434-014-4034-6. ［41］ Caudle AS, Yang WT, Krishnamurthy S, et al. Improved axillary evaluation following neoadjuvant therapy for patients with NodePositive breast cancer using selective evaluation of clipped nodes: implementation of targeted axillary dissection［J］. J Clin Oncol, 2016, 34(10): 1072-1078. DOI: 10.1200/JCO.2015.64.0094. ［42］王丽娜, 李德良, 张南, 等. 淋巴靶向造影剂的研究进展［J］. 中国海洋药物, 2016, 35(2): 95-102. DOI: 10.13400/j.cnki.cjmd.2016.02.015. ［43］ Kim SH, Oh SN, Choi HS, et al. USPIO enhanced lymph node MRI using 3D multi-echo GRE in a rabbit model［J］. Contrast Media Mol Imaging, 2016, 11(6): 544549. DOI: 10.1002/cmmi.1716. ［44］郑红梅, 陈创, 吴新红, 等. 量子点标记探针技术在乳腺癌中的应用进展［J］. 武汉大学学报(医学版), 2015, 36(3): 399-403. DOI: 10.14188/j.1671-8852.2015.03.017. ［45］ Alam F, Yadav N. Potential applications of quantum dots in mapping sentinel lymph node and detection of micrometastases in breast carcinoma［J］. J Breast Cancer, 2013, 16(1): 1-11. DOI: 10.4048/jbc.2013.16.1.1.

[1]	Wang Ying, Liu Nan, Guo Bing. Advances of antibody-drug conjugate in the therapy of metastatic breast cancer [J]. Journal of International Oncology, 2024, 51(6): 364-369.
[2]	Sa Qiang, Xu Hangcheng, Wang Jiayu. Advances in immunotherapy for breast cancer [J]. Journal of International Oncology, 2024, 51(4): 227-234.
[3]	Yang Zhi, Lu Yiqiao, Gu Huayan, Ding Jialing, Guo Guilong. Research progress of tumor microenvironment mediated drug resistance in targeted therapy of breast cancer [J]. Journal of International Oncology, 2024, 51(4): 235-238.
[4]	Chen Boguang, Wang Sugui, Zhang Yongjie. Role of serum cholinesterase and inflammatory markers in the prognosis of stage ⅠA -ⅢA breast cancer [J]. Journal of International Oncology, 2024, 51(2): 73-82.
[5]	Gu Huayan, Zhu Teng, Guo Guilong. Breast microbiota and breast cancer： present and future [J]. Journal of International Oncology, 2024, 51(1): 55-58.
[6]	Wang Jing, Xu Wenting. Value of NLR， CEA combined with coagulation indicators in the differential diagnosis of benign and malignant breast nodules with a diameter ≤ 1.0 cm [J]. Journal of International Oncology, 2023, 50(9): 520-526.
[7]	Feng Chengtian, Huang Furong, Cao Shiyu, Wang Jianyu, Nanding Abiyasi, Jiang Yongdong, Zhu Juanying. Relationships between HER2 protein expression and imaging features in HER2 positive breast cancer patients [J]. Journal of International Oncology, 2023, 50(9): 527-531.
[8]	Feng Dongxu, Wu Wei, Gao Pingfa, Wang Jun, Shi Lijuan, Chen Dawei, Li Wenbing, Zhang Meifeng. Effects of miR-451 on glycolysis and apoptosis of breast cancer cells by regulating Rho/ROCK1 pathway [J]. Journal of International Oncology, 2023, 50(8): 449-456.
[9]	Pan Shulan, Liu Chang, He Ping. Effect of fritinib on angiogenesis, tumor growth and IRE1-ASK1-JNK pathway in triple negative breast cancer [J]. Journal of International Oncology, 2023, 50(8): 457-462.
[10]	Wang Wende, Zeng De. Research progress on the mechanism of endocrine therapy resistance for breast cancer [J]. Journal of International Oncology, 2023, 50(6): 352-356.
[11]	Li Qingshan, Xie Xin, Zhang Nan, Liu Shuai. Research progress on the application of combining radiotherapy and systemic therapy in breast cancer [J]. Journal of International Oncology, 2023, 50(6): 362-367.
[12]	Fan Mengsi, Lu Yaping, Yan Li. Analysis of clinicopathologic features of false negative sentinel lymph nodes in patients with endometrial cancer [J]. Journal of International Oncology, 2023, 50(5): 274-279.
[13]	Zhu Jun, Huang Meijin, Li Yuan, Liu Zegang, Xun Xin, Chen Hong. Research progress on targeted therapy of breast cancer with low expression of HER2 [J]. Journal of International Oncology, 2023, 50(4): 236-240.
[14]	Zhou Ting, Xu Shaohua, Mei Lin. Efficacy and safety of bevacizumab combined with capecitabine in the treatment of advanced breast cancer [J]. Journal of International Oncology, 2023, 50(3): 144-149.
[15]	Li Lixi, Zhang Di, Luo Yang, Ma Fei. Clinical application of PARP inhibitors in breast cancer [J]. Journal of International Oncology, 2023, 50(2): 91-96.

Tracers′ clinical application status in the sentinel lymph node biopsy of breast cancer

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments